Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
A randomised pilot Phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer
2009
Endovascular Stent–Graft Placement for the Treatment of Acute Aortic Dissection
1999 Standout
Prevention of febrile neutropenia: use of prophylactic antibiotics
2009
Cloning and characterization of a mammalian proton-coupled metal-ion transporter
1997 StandoutNature
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
2008
Breast cancer
2016 Standout
Label-retaining cells reside in the bulge area of pilosebaceous unit: Implications for follicular stem cells, hair cycle, and skin carcinogenesis
1990 Standout
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
2009
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
2008
Randomized Study to Compare PTA Alone versus PTA with Palmaz Stent Placement for Femoropopliteal Lesions
2001
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial
2007
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
2008
Development of a new G-CSF product based on biosimilarity assessment
2009
suc1 is an essential gene involved in both the cell cycle and growth in fission yeast
1986 StandoutNobel
Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial
2008
Principles of nanoparticle design for overcoming biological barriers to drug delivery
2015 Standout
Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
2007
Kinetics of Neutrophils in Mice Exposed to Radiation and/or Granulocyte Colony-Stimulating Factor Treatment
2013
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
1994 StandoutNature
Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
Drug development from marine natural products
2008 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA)
2012
Iron speciation at physiological pH in media containing ascorbate and oxygen
1993
Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force
2015
Rapid translocation of nanoparticles from the lung airspaces to the body
2010 StandoutNobel
Hepatocellular carcinoma
2012 Standout
Second international consensus guidelines for breast cancer in young women (BCY2)
2016
Radioembolization with Yttrium-90 Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Hematopoietic growth factors: ESMO Recommendations for the applications
2009
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study
2008
Plain and Covered Stent-Grafts: In Vitro Evaluation of Characteristics at Three-dimensional MR Angiography
1999
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy
2007
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)
2017
Variations in compliance to quality indicators by age for 41,871 breast cancer patients across Europe: A European Society of Breast Cancer Specialists database analysis
2015
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
2005
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Design considerations for tumour-targeted nanoparticles
2009 StandoutNobel
Broad-Spectrum Antibiotic or G-CSF as Potential Countermeasures for Impaired Control of Bacterial Infection Associated with an SPE Exposure during Spaceflight
2015 StandoutNobel
Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery
2006 Standout
Nanomedicine
2006
Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term Survival
2010
Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer
2008
Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma
2007
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Frontiers in cancer nanomedicine: directing mass transport through biological barriers
2010
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes
2011
Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery
2012 Standout
Hindlimb Suspension and SPE-Like Radiation Impairs Clearance of Bacterial Infections
2014 StandoutNobel
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia
2003
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma
2003
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
2007
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
2010 Standout
Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
2007
Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy
2003
Treatment of Aortic Dissections with a Percutaneous Intravascular Endoprosthesis: Comparison of Covered and Bare Stents
1994
Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary Prevention
2007 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma
2006
ReviewPart of the Series: From Dietary Antioxidants to Regulators in Cellular Signalling and Gene ExpressionReview: When is an antioxidant not an antioxidant? A review of novel actions and reactions of vitamin C
2005
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications
2010
XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
2009
Quality of Life and Chemotherapy-induced Neutropenia
2005
Chemotherapy in Early Breast Cancer: When, How and Which One?
2014
Effective drug delivery by PEGylated drug conjugates
2003
Radioembolization with 90Yttrium Microspheres: A State-of-the-Art Brachytherapy Treatment for Primary and Secondary Liver Malignancies
2006
Serum Pegfilgrastim Concentrations During Recovery of Absolute Neutrophil Count in Patients with Cancer Receiving Pegfilgrastim After Chemotherapy
2007
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Chemotherapy‐induced neutropenia
2004
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy
2009
Pharmacokinetic Consequences of Pegylation
2006
Complementary Chimeric Isoforms Reveal Dscam1 Binding Specificity In Vivo
2012 StandoutNobel
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Drug Discovery and Natural Products: End of an Era or an Endless Frontier?
2009 StandoutScience
Practical Approach to Triple-Negative Breast Cancer
2017
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer
2005 Standout
Perspectives on clonogenic tumor cells, stem cells, and oncogenes.
1984
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Breast Cancer Treatment
2019 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Nanoparticles in Photodynamic Therapy
2015 Standout
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
2010
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases.
1985
Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform
2011 Standout
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Nanoparticle Size and Surface Chemistry Determine Serum Protein Adsorption and Macrophage Uptake
2011 Standout
Genetic interactions affecting touch sensitivity in Caenorhabditis elegans.
1996 StandoutNobel
Risk Models for Predicting Chemotherapy-Induced Neutropenia
2005
A suppressor mutation in the nematode acting on specific alleles of many genes
1978 StandoutNatureNobel
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide
2005
Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer
2005
First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
2005
Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma
2003
Ionizing Radiation Selectively Reduces Skin Regulatory T Cells and Alters Immune Function
2014 StandoutNobel
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
2006
Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study
2003
Metal–Organic Frameworks in Biomedicine
2011 Standout
pH-Operated Nanopistons on the Surfaces of Mesoporous Silica Nanoparticles
2010 StandoutNobel
Mechanisms of Suppression
1973
Tissue- and Organ-Selective Biodistribution of NIR Fluorescent Quantum Dots
2009 StandoutNobel
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
par-6, a gene involved in the establishment of asymmetry in early C. elegans embryos, mediates the asymmetric localization of PAR-3
1996 StandoutNobel
Works of Michael A. Savin being referenced
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
2009
Regional Yttrium-90 Microsphere Treatment of Surgically Unresectable and Chemotherapy-Refractory Metastatic Liver Carcinoma
2006
Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with Taxanes
2007 Nobel
Reduction of Metastatic Load to Liver after Intraarterial Hepatic Yttrium-90 Radioembolization as Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomographic Imaging
2005
Gadolinium Enhanced MR Imaging of Vascular Stents
1990
Expandable tubular stents for treatment of arterial occlusive diseases: experimental and clinical results. Work in progress.
1990
Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors
2009
Flexible tantalum stents implanted in aortas and iliac arteries: effects in normal canines.
1990
Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim inchemotherapy-induced neutropenia: a multicenterdose-finding study in women with breast cancer
2002
Growth suppression of human leukemic cells in vitro by L-ascorbic acid.
1980
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer
2006
Improved growth of in vitro colonies in human acute leukemia with the feeding culture method.
1977
Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)
2007
Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
2002
Cystathionine Synthesis in Yeast: an Alternative Pathway for Homocysteine Biosynthesis
1972
Long term disease control in taxane-refractory metastatic breast cancer treated with nab paclitaxel
2004 Nobel
Iron Transport by Isolated Rat Intestinal Mucosal Cells
1978